99
Participants
Start Date
February 24, 2021
Primary Completion Date
March 24, 2023
Study Completion Date
March 24, 2023
Wearable device
As a low-interventional procedure, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
Aichi Cancer Center Hospital, Nagoya
Nagoya City University Hospital, Nagoya
National Cancer Center Hospital East, Kashiwa
Shikoku Cancer Center, Matsuyama
Hokkaido Cancer Center, Sapporo
Sunagawa City Medical Center, Sunagawa
University of Tsukuba Hospital, Tsukuba
Sakai City Medical Center, Sakai
Saitama Cancer Center, Kita-adachi-gun
Seirei Hamamatsu General Hospital, Hamamatsu
Hamamatsu University Hospital, Hamamatsu
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Bunkyo-ku
Cancer Institute Hospital of JFCR, Koto-ku
Toranomon Hospital, Minato
Akita University Hospital, Akita
Fukushima Medical University Hospital, Fukushima
Gifu University Hospital, Gifu
Hiroshima Prefectural Hospital, Hiroshima
Kyoto University Hospital, Kyoto
Okayama University Hospital, Okayama
Lead Sponsor
Japan Breast Cancer Research Group
OTHER
Pfizer
INDUSTRY